<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35255449</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1773-0449</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>32</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Feb</Month>
              <Day>25</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal de mycologie medicale</Title>
          <ISOAbbreviation>J Mycol Med</ISOAbbreviation>
        </Journal>
        <ArticleTitle>A novel method for predicting the efficacy of topical drugs on onychomycosis: A comparison of efinaconazole and luliconazole.</ArticleTitle>
        <Pagination>
          <StartPage>101259</StartPage>
          <MedlinePgn>101259</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mycmed.2022.101259</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1156-5233(22)00016-6</ELocationID>
        <Abstract>
          <AbstractText>To be effective against onychomycosis, topically applied drugs have to reach the infection site at an effective concentration to exert antifungal activity against the parasitic form of dermatophytes. We established a novel in vitro method for predicting drug efficacy at the infection site and verified the method by comparing the efficacy of two azole class topical anti-onychomycosis drugs. To predict drug efficacy in the nail plate, a human nail permeability test was conducted and the activities of the free-drugs in the upper, middle, and lowest layers of the nail plate were determined by measuring the growth inhibitory zone. Efinaconazole permeated the nail more efficiently than luliconazole, and the amount of efinaconazole in the middle and lowest layers was higher compared with that of luliconazole. Efinaconazole demonstrated antifungal activities at the concentrations in all of the nail layers, whereas luliconazole was only active at the concentrations in the upper and middle layers. The results could be explained by differences in their affinity for keratin and nail permeability. The established method enables the evaluation of nail permeability and anti-arthrospore activity of free-drugs in the nail plate to predict drug efficacy. This method will be useful for new topical drug development.</AbstractText>
          <CopyrightInformation>Copyright Â© 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Masumoto</LastName>
            <ForeName>Akane</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan. Electronic address: masumoto_akane@kaken.co.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Takagi</LastName>
            <ForeName>Masashi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacokinetics and Safety Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 301 Gensuke, Fujieda-shi, Shizuoka 426-8646, Japan. Electronic address: takagi_masashi@kaken.co.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sugiura</LastName>
            <ForeName>Keita</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan. Electronic address: sugiura_keita@kaken.co.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Matsuda</LastName>
            <ForeName>Yoshiki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacokinetics and Safety Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 301 Gensuke, Fujieda-shi, Shizuoka 426-8646, Japan. Electronic address: matsuda_yoshiki@kaken.co.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakamura</LastName>
            <ForeName>Saki</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacokinetics and Safety Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 301 Gensuke, Fujieda-shi, Shizuoka 426-8646, Japan. Electronic address: nakamura_saki@kaken.co.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tatsumi</LastName>
            <ForeName>Yoshiyuki</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Pharmacology Department, Drug Research Center, Kaken Pharmaceutical Co., Ltd., 14 Shinomiya, Minamigawara-cho, Yamashina-ku, Kyoto 607-8042, Japan. Electronic address: tatsumi_yoshiyuki@kaken.co.jp.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>25</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>France</Country>
        <MedlineTA>J Mycol Med</MedlineTA>
        <NlmUniqueID>9425651</NlmUniqueID>
        <ISSNLinking>1156-5233</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Antifungal activity</Keyword>
        <Keyword MajorTopicYN="N">In vitro method</Keyword>
        <Keyword MajorTopicYN="N">Nail permeability</Keyword>
        <Keyword MajorTopicYN="N">Onychomycosis</Keyword>
        <Keyword MajorTopicYN="N">Topical antifungal drug</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest All authors have the following conflict of interest: The authors are employees and stockholders of Kaken Pharmaceutical Co., Ltd. Kaken Pharmaceutical Co., Ltd., which discovered Clenafin/Jublia, a topical onychomycosis treatment product that contains efinaconazole. Jublia is commercialized in the United States and Canada by Bausch Health Companies Inc.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>8</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>7</Day>
          <Hour>20</Hour>
          <Minute>14</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35255449</ArticleId>
        <ArticleId IdType="doi">10.1016/j.mycmed.2022.101259</ArticleId>
        <ArticleId IdType="pii">S1156-5233(22)00016-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
